Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen has announced that, following the shareholder approval of Octagen, it has completed the purchase of all of the assets related to OBI-1.
Subscribe to our email newsletter
Ipsen paid accordingly to Octagen an upfront milestone of $10.5 million. Immediately following the effective transfer of all of the assets related to OBI-1, Ipsen will redeem its stake in Octagen.
OBI-1 is a recombinant porcine Factor VIII. Since porcine FVIII (pFVIII) possesses low cross reactivity to anti-hFVIII antibodies, it is expected that OBI-1 can be used to stop bleeding in hemophilia patients with inhibitor using the same natural pathway as human Factor VIII for non inhibitor patients.